Eligible HIV-infected patients with clinically evident lipoatrophy despite treatment with efavirenz and fixed-dose combination of thymidine nucleoside analogues will be informed and asked to enroll in the study; will be randomized (1:1) into two branches, A: EFV + Fixed combinations of analogue tenofovir + emtricitabine.B (experimental): LPV/r + combination of correspondent analogues. The main variable is the evaluation of the absolute change in limb fat mass at 24 months from baseline in both groups.

CT to Assess the Effect on the Subcutaneous Fat of Change of EFV for LPV/r in HIV-infected Patients Who Developed Lipoatrophy and Remains Despite Treatment With Efavirenz and Fixed-dose Combination of no Thymidine Nucleoside Analogues.

Patients in treatment with Sustiva(r)+Truvada(r); or Sustiva (r)+Kivexa(r).

HIV-ARN < 50 copies/mL in the las six months.

Clinically evident lipoatrophy (moderate or severe).

Negative pregnancy test.

Signed informed consent.

Exclusion Criteria:

Evidence of failure or mutation to therapy with protease inhibitors.

Patients that can not be treated with LPV/r.

Mild lipoatrophy.

History of alcoholism or drug addiction that discourages participation in the study.

Pregnancy or breastfeeding.

Documented current or 4 weeks prior opportunistic infection.

Creatinin clearance < 60mL/min.

Concomitant use of nephrotoxic drugs or immunosuppressants.

Actual treatment with systemic corticosteroids, IL-2 or chemotherapy.

Patients under treatment with other drugs in investigation.

Acute hepatitis.

Any other disease that discourages participation.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00978237